文献速递胸部肿瘤支持与姑息治疗

肺癌合并COVID-19患者免疫检查点阻断期间的非典型皮肤表现

Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2020-07-09

本文报告两例肺癌合并COVID-19患者,无呼吸系统受损但出现非典型且严重的皮肤表现,可能受长期使用抗PD-1抗体影响。文章还引用湖北抗癌协会多中心研究,指出肺癌患者感染COVID-19后死亡风险、ICU需求、重症或危重症症状风险及有创机械通气使用均增加。

要点

  • 肺癌合并COVID-19患者即使无呼吸受损,也应警惕非典型严重皮肤表现。
  • 长期使用抗PD-1抗体可能影响此类皮肤表现的发生。
  • 肺癌患者感染COVID-19后重症和死亡风险更高。

核心结论

  • 肺癌合并COVID-19患者可出现无呼吸受损的非典型严重皮肤表现,可能与长期使用抗PD-1抗体有关。

研究设计与样本

  • 病例报告,报告两例肺癌合并COVID-19患者的临床经过。

主要发现

  • 两例肺癌合并COVID-19患者均无呼吸系统受损,但出现非典型且严重的皮肤表现。
  • 上述皮肤表现可能受长期使用抗PD-1抗体影响。
  • 湖北抗癌协会多中心研究记录肺癌患者感染COVID-19后死亡风险、ICU需求、重症或危重症症状风险及有创机械通气使用增加。

临床怎么用

  • 对肺癌合并COVID-19患者,即使无呼吸受损,也应关注非典型严重皮肤表现并考虑抗PD-1抗体长期使用的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A new coronavirus, named severe acute respiratory syndrome-coronavirus-2 by the WHO, has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, the People's Republic of China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100,000 deaths. With approximately 20 million new cases globally per year, cancer affects a substantial portion of the population. Individuals affected by cancer are more susceptible to infections owing to coexisting chronic diseases (cardiovascular, pulmonary, and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and the anticancer treatment. As a consequence, patients with malignancies, especially those with lung cancer who develop coronavirus disease 2019, experience more difficult outcomes. A recent multicenter study carried out by the Hubei Anti-Cancer Association has also documented that patients with lung cancer had an increased risk of death, intensive care unit requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here, we present two representative cases of patients with lung cancer and coronavirus disease 2019 without respiratory compromise and with atypical and severe skin manifestations-findings that could be influenced by the long-term use of anti-programmed cell death protein 1 antibody.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rolfo C, Cardona AF, Ruiz-Patiño A, et al. Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer. J Thorac Oncol. 2020. PMID: 32653627. doi:10.1016/j.jtho.2020.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。